Cannon Global Investment Management LLC Invests $723,000 in Cellebrite DI Ltd. $CLBT

Cannon Global Investment Management LLC bought a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 52,500 shares of the company’s stock, valued at approximately $723,000. Cellebrite DI accounts for 1.4% of Cannon Global Investment Management LLC’s holdings, making the stock its 22nd biggest holding.

Other institutional investors and hedge funds have also modified their holdings of the company. Blue Trust Inc. raised its stake in shares of Cellebrite DI by 5.6% during the 1st quarter. Blue Trust Inc. now owns 24,790 shares of the company’s stock worth $342,000 after buying an additional 1,325 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Cellebrite DI by 45.1% during the 4th quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after purchasing an additional 1,238 shares in the last quarter. Invesco Ltd. lifted its stake in Cellebrite DI by 0.8% in the 4th quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after buying an additional 43,041 shares in the last quarter. Corient Private Wealth LLC increased its position in Cellebrite DI by 29.8% during the fourth quarter. Corient Private Wealth LLC now owns 107,145 shares of the company’s stock worth $1,932,000 after buying an additional 24,596 shares in the last quarter. Finally, Vident Advisory LLC lifted its position in shares of Cellebrite DI by 7.1% in the fourth quarter. Vident Advisory LLC now owns 50,887 shares of the company’s stock valued at $917,000 after acquiring an additional 3,372 shares in the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CLBT. DA Davidson initiated coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price for the company. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Needham & Company LLC cut their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Finally, Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $13.76 on Friday. The firm has a market capitalization of $3.43 billion, a price-to-earnings ratio of 49.14, a price-to-earnings-growth ratio of 1.56 and a beta of 1.17. Cellebrite DI Ltd. has a one year low of $11.02 and a one year high of $19.98. The company has a 50 day moving average price of $13.21 and a 200 day moving average price of $14.73.

Insider Activity at Cellebrite DI

In related news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 13,269 shares of company stock worth $169,592. Corporate insiders own 5.70% of the company’s stock.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.